GTC Biotherapeutics (fka GTCB)

[croumagnon]

The only silver lining is that now the float is down to the 10 Million shares range, which means good news could send the stock flying. On the other hand, clearly this was done for the sake of further financing, which means that I expect the stock to open tomorrow at around $3 and quickly degenerate to somewhere around $2. The big question becomes: is GTCB worth a gamble for about $2 a share ($0.2 of the old shares)?

We know the technology works, that ATryn is approved in the US and the EU, and that transgenic has a huge future; but we also know that management stinks, that their financial situation is abysmal, and that LFB is about to devour them for a song...